XLRN-517 is under clinical development by Acelyrin and currently in Phase II for Chronic Urticaria Or Hives. According to GlobalData, Phase II drugs for Chronic Urticaria Or Hives have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XLRN-517’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XLRN-517 overview
Acelyrin overview
Acelyrin is a biopharma company that identifies, acquires and accelerates the development and commercialization of transformative medicines.It focuses on creating value for patients and shareholders. The Company’s products includes izokibep, Lonigutamab (anti-IGF-1R), XLRN-517 (anti-C-KIT). It actively investigates the potential of izokibep and other programs in diseases where differentiated therapeutic approaches are required to address unmet patient needs. It can access promising therapeutic programs through Acelyric global network of relationships across pharma and biotech, finance and academia.The company collaborates with partners, pharmaceutical companies, early-stage start-ups and academicians in identifying and developing products. It is also involved in the development of Los Angeles Biotech Hub. Acelyrin is headquartered in Agoura Hills, California, the US.
For a complete picture of XLRN-517’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
